Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2015)
27 slides from Vita Life Sciences's shareholder meeting presentation, May 25, 2015
Slide 1: Welcome to the 2015 Vita Life Sciences Annual General Meeting
Welcome to the 2015 Vita Life Sciences Limited Annual General Meeting herbsofgold vitascience ViraLife | Enriching Lives .Since 1947 25 May 2015 VS
Slide 2: Chairman's Welcome Address
Chairman’s Welcome Address
Slide 3: Kuala Lumpur Headquarters
Kuala Lumpur Headquarters
Slide 4: Chairman's Welcome, Managing Director's Review, Resolutions, Q&A
1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer Time
Slide 5: Managing Director's Review
Managing Directors Review
Slide 6: Asia Pacific pharmaceutical and healthcare business
Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements 800 registered sku of vitamins and supplements sold in 8 countries in the Asia Pacific region 2 major brands 1. VitaHealth: products s
Slide 7: Establishment of an operational platform in Indonesia
The establishment of an operational platform in Indonesia represents a watershed moment for VSC as it has now achieved strategic goals set at IPO: Consolidate business in 3 established countries: Australia, Malaysia and Singapore Expansion of marketing channels in 3 established countries Expan
Slide 8: Vita Life Sciences has built a portfolio of recognised brands
Insert VH logo Insert HoG logo Insert VL logo Country presence Malaysia Australia - - - At IPO (2007) Singapore - Expanded (2008 on) China Singapore Malaysia Australia Thailand Vietnam Indonesia (H2 2015) Total no. of products ~450 ~200 ~30 ~20 (sku) on sale Product offering Supplements Vita
Slide 9: 2008 vs 2014 revenue by geography
2008 revenue by geography 2014 revenue by geography Other Asia 1% Other Asia 15% Singapore 15% Australia Australia 46% 38% Asia Asia Singapore 54% 15% 62% Malaysia OTC 27% Malaysia OTC 32% Total revenue: $14m Total revenue: $37m Revenue has grown from both consolidation of established businesses and
Slide 10: Revenue, EBIT and EBIT Margin 2008 vs 2014
Revenue EBIT EBIT Margin (A$m) (A$m) (%) 40 8 20 16 30 6 12 20 4 8 10 2 4 0 0 0 2008 2014 2008 2014 2008 2014 9
Slide 11: Group wide, margins have stabilised at a sustainable level
Group wide, margins have stabilised at a sustainable level. VSC now focussed on revenue growth. VSC will leverage off established platform for next evolutionary step: Reputable brands recognised in 7 countries Selected 50m+ population South East Asian countries entered Proven management team a
Slide 12: Managing Director
Managing Director CEO Australia CEO Malaysia OTC & Singapore New Markets A O’Keefe Vacant Expansion and Operation Appointed 2014 Candidates being sought China Indonesia Malaysia MLM Thailand Vietnam 11
Slide 13: CEO of Australia, Mr Andrew O'Keefe
CEO of Australia, Mr Andrew O’Keefe, commenced October 2014 Mr O’Keefe’s key deliverables are: 1. Consolidate Herbs of Gold market position 2. Introduce Vita Sciences brand to marketplace and build a sustainable business 3. Identify opportunities to leverage Group’s position in to new customer group
Slide 14: The CEO's key deliverables will be
VSC is seeking a CEO to oversee combined Malaysian and Singaporean established businesses The CEO’s key deliverables will be: 1. Expand the Vita Health brand in Singapore and Malaysia 2. Introduce Herbs of Gold brand to marketplace and build a sustainable business 3. Identify opportunities to levera
Slide 15: Operations established, however remain in their infancy
Operations established, however remain in their infancy Through management build out in established businesses, Mr Tie’s extra capacity will allow him to drive the new markets: China: Regulatory hurdles to be navigated Thailand: Adapting product pricing and positioning to changing market conditi
Slide 16: Malaysian central facility will increase operational capabilities
Malaysian central facility will increase VSC’s operational capabilities: On-site new packing plant will enable VSC to increase customer service; On-site laboratory positions VSC to meet more stringent product efficacy pharmaceutical regulations associated with the inception of the ASEAN free tra
Slide 17: Australia sales and EBIT up against 2014
Two major markets: Australia sales and EBIT up against 2014 Malaysia down on 2014 as a result of GST introduction Other markets: Singapore up on 2014, off a low 2014 base China down on 2014, off high 2014 base Thailand remains problematical Vietnam progressing well Despite a soft start i
Slide 18: Appendix
Appendix
Slide 19: Year ended 31 December
Year ended 31 December 2014 2013 Change $m $m % Revenue 36.58 35.41 3.3% EBITDA 7.00 5.62 24.6% EBIT 6.88 5.51 24.9% Profit before tax 6.92 5.52 25.4% Profit after tax (1) 7.28 4.75 53.3% EPS (Diluted – cents) 12.84 8.42 52.5% Dividend (cents / share) 3.50 3.00 16.7% (1) Profit After Tax includes a
Slide 20: Balance Sheet as at 31 December
Balance Sheet as at 31 December 2014 2013 $m $m Current assets 20.81 20.49 Non-current assets 9.46 1.52 Total assets 30.27 22.01 Current liabilities (5.53) (5.68) Non-current liabilities (3.17) (0.06) Total Liabilities (8.71) (5.74) Net Assets 21.56 16.27 19
Slide 21: Cash Flow
Cash Flow 2014 2013 $m $m Receipts from customers 38.97 38.86 Payments to suppliers and employees (31.95) (33.54) Gross operating cash flow 7.02 5.32 EBITDA 7.00 5.62 Gross operating cash flow / EBITDA 100.3% 94.7% Net interest received 0.12 0.07 Income tax paid (1.02) (0.56) Operating cash flows 6.
Slide 22: Chairman's Address, Managing Director's Review, Resolutions, Q&A
1. Chairman’s Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer Time
Slide 23: Ordinary Resolutions
1. Remuneration Report 2. Re-election of Director – Mr J Tooth 3. Share buy-back 4. Long Term Incentive Plan – Mr E Tie 5. Long Term Incentive Plan – Mr H Townsing
Slide 24: Proxy's Resolutions
PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN TOTALS DISCRETION 1) Adoption of the Remuneration 29,012,488 2,378,176 2,765,441, 8,146 34,164,251 Report 2) Election of Director 33,702,957 159,666 293,482 8,146 34,164,251 (Mr J Tooth) 3) Share Buy-Back 34,036,814 65,020 54,271 8,146 34,164,251 4) Long
Slide 25: Chairman's Address, Managing Director's Review, Resolutions, Q&A
1. Chairman’s Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer Time
Slide 26: Forward-looking statements and important notice
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis
Slide 27: Contact Details
Contact Details Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 26